Related Experiment Video

Updated: Sep 2, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and

Chunyan Shi1,2, Yan Wang1, Jianxin Xue1,3,4

  • 1Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in Immunology
|August 8, 2022
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show promise for non-small-cell lung cancer (NSCLC) with EGFR mutations. Combining ICIs with chemotherapy may improve outcomes, especially for rare mutations, warranting further exploration.

Area of Science:

  • Oncology
  • Immunotherapy
  • Genetics

Background:

  • Immune checkpoint inhibitors (ICIs) offer durable benefits in advanced non-small-cell lung cancer (NSCLC), irrespective of PD-L1 status.
  • Immunotherapy efficacy is suboptimal in EGFR-mutant NSCLC post-tyrosine kinase inhibitor (TKI) resistance.
  • Combining ICIs with chemotherapy improves efficacy compared to monotherapy.

Purpose of the Study:

  • To review preclinical and clinical studies of ICIs for EGFR-mutant NSCLC.
  • To explore the link between EGFR mutations and cancer immunity, focusing on the cancer-immunity cycle.
  • To identify mechanisms of resistance to ICIs and potential countermeasures.

Main Methods:

  • Review of preclinical and clinical studies on ICIs and combination therapies in EGFR-mutant NSCLC.
  • Analysis of EGFR mutations' role in cancer immune response and the cancer-immunity cycle.
  • Exploration of natural resistance mechanisms to ICIs.

Main Results:

  • ICIs combined with chemotherapy demonstrate improved efficacy over monotherapy.
  • Patients with rare EGFR mutations show increased progression-free survival with ICIs compared to sensitive mutations.
  • Understanding EGFR activation in the cancer-immunity cycle is crucial.

Conclusions:

  • Maximizing ICI efficacy in EGFR-mutant NSCLC is a critical area for research.
  • Targeting resistance mechanisms can potentially extend ICI benefits to more patients.
  • Further investigation into combination therapies and rare mutations is warranted.
Keywords:
EGFR mutationimmune checkpoint inhibitorsnon-small-cell lung cancerprogrammed cell death 1programmed cell death ligand 1tumor microenvironment

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
650
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K